Hypha Labs Reports Improved Net Loss and Strategic Shift to New Product Development

Hypha Labs, Inc. reported its financial results for the three months ending December 31, 2025, revealing a net loss of $521,638, a significant improvement from a net loss of $1,339,641 during the same period in 2024. The company did not generate any revenue during this quarter, consistent with the previous year. Operating expenses decreased to $475,020 from $1,305,264, primarily due to a reduction in general and administrative expenses, which fell by 82% to $185,876, largely attributed to the absence of stock-based compensation that had inflated costs in the prior year.

The company's total assets decreased to $391,601 as of December 31, 2025, down from $409,218 at the end of the previous quarter. Current liabilities increased significantly to $1,320,783 from $1,118,955, driven by higher accounts payable and accrued expenses. The total liabilities rose to $2,743,090, compared to $2,512,387 in the prior quarter, reflecting the company's ongoing financial challenges. Hypha Labs also reported a negative working capital of $1,006,193 and an accumulated deficit of $24,170,965, raising concerns about its ability to continue as a going concern.

Strategically, Hypha Labs has shifted its focus from cannabis testing to the development of a new product, the Hypha Micropearl bioreactor, designed to facilitate the home production of nutritionally beneficial mushrooms. The company plans to market this product by late 2026, pending successful testing and development. In the past quarter, Hypha Labs issued 310,063 shares of Series D Preferred stock, generating net proceeds of $57,485, which will support its ongoing operations and product development.

Operationally, the company has not reported any customer counts or user statistics related to its new product line, as it is still in the development phase. The employee headcount remains unspecified, but the company has indicated a need for additional capital to fund its operations and product launch. Hypha Labs is exploring various financing options, including equity and debt securities, to support its transition and growth strategy.

Looking ahead, Hypha Labs faces significant challenges, including the need to secure funding to sustain operations and complete product development. The company has acknowledged the uncertainty surrounding its ability to continue as a going concern, emphasizing the importance of raising capital to avoid potential disruptions in its business. The management's forward-looking statements highlight the intention to pursue additional investments and acquisitions, although there is no guarantee of success in these endeavors.